Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Tian-Kang Guo
Xiang-Yong Hao
Bin Ma
Ke-Hu Yang
Yi-Ping Li
Hong-Ling Li
Yuan-Hui Gu
Hui Cai
Ya-Li Liu
Yuan Li
Wei-Peng Zhan
机构：
[1] The People’s Hospital of Gansu Province,
[2] Evidence-Based Medicine Center of Lanzhou University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2009年 / 135卷
关键词：
Hepatocellular carcinoma; Octreotide; Liver disease; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1685 / 1692
页数：7
相关论文
共 50 条
  • [41] VEGF Pathway-targeted Therapy for Advanced Renal Cell Carcinoma: A Meta-analysis of Randomized Controlled Trials
    刘飞
    陈先国
    彭鄂军
    管维
    李有元
    胡志全
    叶章群
    庄乾元
    Current Medical Science, 2011, 31 (06) : 799 - 806
  • [42] VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials
    Fei Liu
    Xianguo Chen
    Ejun Peng
    Wei Guan
    Youyuan Li
    Zhiquan Hu
    Zhangqun Ye
    Qianyuan Zhuang
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31 : 799 - 806
  • [43] Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials
    Liu, Yingyu
    Kou, Changgui
    Su, Yingying
    Zhang, Yangyu
    You, Yueyue
    Zhang, Lili
    Wang, Mohan
    Fu, Yingli
    Ren, Xiaojun
    Yang, Yanming
    ONCOTARGETS AND THERAPY, 2017, 10 : 2971 - 2980
  • [44] The use of somatostatin or octreotide to prevent post-ERCP pancreatitis: A meta-analysis of randomized, controlled trials
    Lung, E
    GASTROINTESTINAL ENDOSCOPY, 2004, 59 (05) : AB107 - AB107
  • [45] Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials
    Facciorusso, Antonio
    Bellanti, Francesco
    Villani, Rosanna
    Salvatore, Veronica
    Muscatiello, Nicola
    Piscaglia, Fabio
    Vendemiale, Gianluigi
    Serviddio, Gaetano
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (04) : 511 - 518
  • [46] SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A META-ANALYSIS OF THE CONTROL ARMS OF 28 RANDOMIZED TRIALS
    Cabibbo, G.
    Enca, M.
    Latteri, F.
    Genco, C.
    Craxi, A.
    Camma, C.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S285 - S285
  • [47] A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Enea, Marco
    Attanasio, Massimo
    Bruix, Jordi
    Craxi, Antonio
    Camma, Calogero
    HEPATOLOGY, 2010, 51 (04) : 1274 - 1283
  • [48] Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials
    Carolina Marin Comini, Ana Carolina
    de Sousa, Isadora Martins
    Abrahao Reis, Pedro Cotta
    Carvalho, Bruno Murad
    Guedes Camandaroba, Marcos Pedro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials
    An, Jihyun
    Han, Seungbong
    Kim, Ha Il
    Shim, Ju Hyun
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (10) : 2886 - 2900
  • [50] Surrogacy of time to prgression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials.
    Terashima, Takeshi
    Yamashita, Tatsuya
    Arai, Kuniaki
    Toyama, Tadashi
    Kawaguchi, Kazunori
    Kitamura, Kazuya
    Yamashita, Taro
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345